MRM Health NV

What MRM Health NV does

MRM Health NV is a clinical-stage biopharmaceutical company founded in 2020 and headquartered in Ghent, Belgium, that develops microbiome-based Live Biotherapeutic Products (LBPs) for chronic inflammatory, metabolic, and immune-mediated diseases. The company operates through its proprietary CORAL® platform, which integrates a bioinformatics-guided in-human discovery engine, a proprietary microbiome optimization technology, and a breakthrough GMP-compliant manufacturing process that produces multi-strain consortia as a single Drug Substance. Its lead candidate MH002 is a rationally designed six-strain commensal consortium currently in the STARFISH-UC Phase 2b trial (approximately 204 patients across ~60 sites in Europe and the U.S.) for mild-to-moderate ulcerative colitis, supported by FDA Fast Track Designation and IND clearance. The pipeline additionally includes pouchitis (Phase 2a positive), Type 2 Diabetes (with IFF), NAFLD, Parkinson's Disease (observational), and immune-oncology (with Oncode Institute/NKI).

MRM Health has no commercial products and is therefore pre-revenue; the business model is built around developing LBPs through clinical proof-of-concept and then monetizing via strategic pharmaceutical partnerships, licensing deals, and milestone/royalty arrangements. Distribution is currently limited to clinical trial sites, with future commercialization intended through partners with established global pharma distribution networks — most prominently Biocodex, which led the €55M Series B in September 2025. The company is also supported by a Belgian and European investor base including ATHOS, SFPIM, Ackermans & van Haaren, OMX Europe Venture Fund, Qbic II, BNP Paribas Private Equity, IFF, and VIB, with academic partnerships anchored at VIB, KU Leuven, and Ghent University.

The GTM motion is enterprise partnership-driven: clinical data presentations at conferences (DDW, BIO-Europe Spring, Microbiome Movement summits), peer-reviewed publications, and milestone-driven licensing or co-development negotiations with large pharma. Pricing is not publicly disclosed and is not yet relevant commercially; near-term value inflection depends on STARFISH-UC Phase 2b topline induction results expected in Q4 2027.

Name

MRM Health NV

Legal name

MRM Health NV

Website

https://mrmhealth.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

MRM Health NV is a clinical-stage biopharmaceutical company developing microbiome-based Live Biotherapeutic Products using its proprietary CORAL® platform. Its lead candidate MH002 is in Phase 2b for mild-to-moderate ulcerative colitis, with partnerships spanning pharma, biotech, and academic institutions across Europe and the U.S.

Ownership category

akta.pro rank

Product category

Microbiome Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Live Biotherapeutic Products (LBPs) (HLAAAFAA)

akta.pro secondary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Microbiome therapeutics
• Live biotherapeutic products
• Biopharmaceutical development
• Inflammatory bowel disease
• Gut microbiome research

Headquarters

HQ city

Ghent

HQ country

Belgium

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Live Biotherapeutic Products (LBPs): Revenue from development and commercialization of microbiome-based Live Biotherapeutic Products (LBPs) for inflammatory and immune-mediated diseases. As a clinical-stage company, currently in development phase with no commercial revenue. Future revenue expected through product sales following regulatory approval or through licensing/partnerships with pharmaceutical companies.
2. Licensing and Partnership Revenue: Strategic partnerships with pharmaceutical companies for development, manufacturing, and commercialization rights. Includes milestone payments, upfront payments, and potential royalties on approved products.
3. Strategic Collaborations: Collaborations with partners like Biocodex for therapeutic asset development and manufacturing capabilities expansion. May include development milestones, research funding, and commercialization revenues.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

MRM Health is a clinical-stage biopharmaceutical company developing microbiome-based Live Biotherapeutic Products (LBPs) for chronic inflammatory, metabolic, CNS, and immune-oncology diseases. Its lead candidate MH002 is a rationally designed 6-strain bacterial consortium currently in Phase 2b (STARFISH-UC) for mild-to-moderate ulcerative colitis and pouchitis, manufactured via its proprietary CORAL® platform as a single Drug Substance. Future commercialization is planned through licensing and co-development partnerships with pharmaceutical companies.

Product overview

MRM Health NV is a clinical-stage biopharmaceutical company (founded 2020, Ghent, Belgium) developing microbiome-based Live Biotherapeutic Products (LBPs) for chronic diseases with high unmet needs. The company operates through its proprietary CORAL® platform which enables design, optimization, and manufacturing of precision-engineered live bacterial consortia as a single Drug Substance. The lead product is MH002, a rationally designed 6-strain microbial consortium currently in Phase 2b clinical development (STARFISH-UC trial) for mild-to-moderate ulcerative colitis, having received FDA Fast Track Designation. The pipeline includes programs in inflammatory bowel diseases (IBD), pouchitis, Type 2 Diabetes (with IFF), Parkinson's Disease, NAFLD, and immune-oncology (with Oncode Institute/NKI).

Differentiator

Problem solved

Functional benefit

Products and services

• MH002 Lead rationally designed Live Biotherapeutic Product (LBP) candidate composed of six well-characterized commensal bacterial strains, currently in Phase 2b development (STARFISH-UC) for mild-to-moderate ulcerative colitis and pouchitis. Granted FDA Fast Track Designation and FDA IND clearance, with positive Phase 2a safety and efficacy data.
• Type 2 Diabetes Program Microbiome-based therapeutic program in metabolic diseases, specifically Type 2 diabetes, developed in collaboration with IFF (International Flavors & Fragrances). Achieved preclinical development targets and is being advanced toward clinical development for metabolic disease indications.
• Parkinson's Disease Program Observational, cross-sectional clinical research program studying the role of the small intestinal microbiome in Parkinson's Disease and identifying PD-specific microbial and metabolic fingerprints, conducted in collaboration with Nimble Science and University of Calgary, Canada.
• NAFLD Program Preclinical incubator program in liver diseases including non-alcoholic fatty liver disease (NAFLD) using a 9-strain live bacterial consortium derived from the CORAL® platform, with preclinical results showing delayed disease progression and liver fibrosis.
• Immune-Oncology Program Strategic collaboration program with Oncode Institute and Netherlands Cancer Institute (NKI), led by Prof. Emile Voest, developing microbiome-based live biotherapeutic products designed to enhance the efficacy of immune checkpoint inhibitors in cancer treatment.

Quantifiable outcome

• Phase 2a results showed excellent safety, mucosal healing, anti-inflammatory activity, and induction of clinical remission over eight weeks of treatment with no adverse reactions observed
• +3 more outcomes

Segments5 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature6 records

Partnerships

Eight partnerships are on record, tiered core, minor and major.

• Oncode Institute and Netherlands Cancer Institute (NKI)coreStrategic or Co-development Partner · 17 December 2025Strategic collaboration with research group of Prof. Emile Voest to develop novel live biotherapeutic products to improve efficacy of immune checkpoint inhibitors in cancer treatment.
• BiocodexcoreStrategic or Co-development Partner · 4 September 2025Series B financing led by Biocodex with €55 million investment and strategic partnership focused on developing therapeutic assets and manufacturing capabilities, as well as expanding the microbiome-based biotherapeutic product pipeline.
• University of CalgaryminorStrategic or Co-development Partner · 20 February 2024Collaboration in Parkinson's Disease study to identify PD-specific microbial and metabolic fingerprints in small intestinal fluid and blood.
• IFF (International Flavors & Fragrances)majorStrategic or Co-development Partner · 12 December 2022Type-2 Diabetes Program collaboration achieving preclinical development targets, advancing research for metabolic diseases to clinical development stage. Second milestone achieved.
• DuPont Nutrition & Biosciences (now part of IFF)majorStrategic or Co-development Partner · 19 February 2020First industry collaboration in the field of metabolic diseases with over €14 million investment boost to advance microbiome-based therapeutics development.
• VIB (Flemish Institute for Biotechnology)coreStrategic or Co-development PartnerStrategic partnership with leading life sciences institute VIB, with top research groups in both microbiome analysis and ecology and in host biology and disease research. Part of Center of Expertise for microbiome R&D.
• KU LeuvencoreStrategic or Co-development PartnerAcademic research partnership with KU Leuven for microbiome research and development, particularly in host-microbiome interactions and immunity.
• Ghent UniversitycoreStrategic or Co-development PartnerPartnership with Ghent University for microbiome research and development, leveraging academic expertise in microbial ecology and host-microbiome interactions.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Seres Therapeutics: Clinical-stage microbiome therapeutics company that developed VOWST, the first FDA-approved oral microbiome therapy (with Nestlé Health Science). Both companies develop rationally designed bacterial consortia for serious diseases using platform-based discovery and manufacturing approaches.
• Vedanta Biosciences: Clinical-stage company developing defined bacterial consortia as live biotherapeutic products for gastrointestinal and immunological diseases. Direct competitor in IBD and similar indication space, with parallel platform-based consortia development.
• MaaT Pharma: European clinical-stage microbiome therapeutics company with lead candidates in acute graft-versus-host disease and IBD. Targets overlapping inflammatory disease indications and uses standardized microbiome-based therapeutic approaches.
• Enterome: Clinical-stage microbiome and immune-oncology company developing OncoMimics and other bacterial-derived therapeutics for cancer and IBD. Direct peer in IBD indications and shared microbiome-modality expertise.
• Finch Therapeutics: Clinical-stage microbiome therapeutics company developing Full-Spectrum Microbiota and defined-consortium products for inflammatory and infectious diseases. Despite recent pipeline restructuring, remains a direct competitor in the microbiome therapeutics space.
• Second Genome: Clinical-stage biotech developing microbiome-derived therapeutics for inflammatory bowel disease and other conditions. Direct competitor in IBD-focused microbiome drug development.

Emerging players

• Assembly Biosciences: Biotech with a microbiome-derived therapeutic platform focused on inflammatory diseases. Overlaps with MRM Health in rational design of microbiome-based interventions, though primary pipeline is in virology.
• Eligo Bioscience: Emerging microbiome-focused biotech developing engineered phage-based therapeutics targeting the microbiome for inflammatory and other diseases. Adjacent modality to MRM Health's live biotherapeutic consortia approach.

Broad incumbents

• Ferring Pharmaceuticals (REBYOTA): Global pharma company that commercialized REBYOTA, the first FDA-approved fecal microbiota product (for recurrent C. difficile infection). Represents the incumbent commercial pathway for microbiome-based therapeutics.
• Ferring Pharmaceuticals / Nestlé Health Science (VOWST): Nestlé Health Science partnered with Seres Therapeutics to bring VOWST to market as the first FDA-approved oral microbiome therapy, with Hans-Jürgen Wörle from Nestlé now on MRM Health's board. Represents the established commercial template in microbiome therapeutics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutu.be/bouC52ZkaTg

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds4 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MRM Health NV